BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemorrhagic Stroke
Conditions
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Trial Timeline
Dec 24, 2017 → May 13, 2020
NCT ID
NCT03338998About BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tablet
BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tablet is a phase 2 stage product being developed by Novartis for Hemorrhagic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03338998. Target conditions include Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03338998 | Phase 2 | Completed |
Competing Products
10 competing products in Hemorrhagic Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 44 |
| ALN-6400 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| AVI-7537 | United Therapeutics | Phase 1 | 30 |
| AVI-7288 | United Therapeutics | Phase 1 | 30 |
| Placebo + AVI-6002 | United Therapeutics | Phase 1 | 30 |
| AVI-6003 + Placebo | United Therapeutics | Phase 1 | 30 |
| Ad26.ZEBOV + MVA-BN-Filo | Bavarian Nordic | Phase 3 | 74 |
| Tranexamic acid first, than placebo + First placebo, than Tranexamic acid. | Baxter | Phase 3 | 74 |
| Ribavirin (Virazole) Injection | Bausch Health | Phase 2 | 47 |
| BGE-117, 4mg + BGE-117, 12mg | BioAge Labs | Phase 2 | 47 |